Biogen (BIIB) Capital Expenditures (2009 - 2026)

Biogen's Capital Expenditures history runs 18 years deep, the most recent figure standing at $51.2 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 38.01% year-over-year to $51.2 million; the TTM figure through Mar 2026 stood at $167.9 million (up 15.87% YoY), while the FY2025 annual figure was $153.8 million, changed 0.07% from the prior year.
• Capital Expenditures was $51.2 million for Q1 2026 at Biogen, up from $43.9 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $86.4 million in Q4 2022 to a low of $26.6 million in Q2 2025.
• Historically, Capital Expenditures has averaged $51.5 million across 5 years, with a median of $46.2 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Capital Expenditures surged 92.41% in 2023, then slumped 52.83% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $86.4 million in 2022, then declined by 24.54% to $65.2 million in 2023, then sank by 39.72% to $39.3 million in 2024, then increased by 11.7% to $43.9 million in 2025, then increased by 16.63% to $51.2 million in 2026.
• The last three Capital Expenditures figures came in at $51.2 million (Q1 2026), $43.9 million (Q4 2025), and $46.2 million (Q3 2025), per Business Quant data.